Terns Pharmaceuticals Inc (TERN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
May 17, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals SG&A Expense (TTM): 38.82M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 38.82M |
| December 31, 2023 | 39.06M |
| September 30, 2023 | 38.63M |
| June 30, 2023 | 25.41M |
| March 31, 2023 | 23.82M |
| December 31, 2022 | 22.41M |
| September 30, 2022 | 21.66M |
| June 30, 2022 | 21.24M |
| Date | Value |
|---|---|
| March 31, 2022 | 20.68M |
| December 31, 2021 | 19.55M |
| September 30, 2021 | 15.13M |
| June 30, 2021 | 13.75M |
| March 31, 2021 | 11.38M |
| December 31, 2020 | 8.996M |
| September 30, 2020 | 10.39M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
8.996M
Minimum
Dec 2020
39.06M
Maximum
Dec 2023
22.06M
Average
21.24M
Median
Jun 2022
SG&A Expense (TTM) Benchmarks
| Viking Therapeutics Inc | 37.46M |
| Eli Lilly and Co | 6.912B |
| Pfizer Inc | 14.85B |
| Amgen Inc | 6.729B |
| Madrigal Pharmaceuticals Inc | 172.76M |